Sulodexide modifies intravascular homeostasis what affects function of the endothelium

Advances in Medical Sciences

Volumn 58, Issue 2, 2013, Pages 304-310

  Polubinska A ^a   Staniszewski, R ^a   Baum, E ^a   Suminska Jasinska K ^a   Breborowicz A ^a,b  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b The President Stanis aw Wojciechowski State University of Applied Sciences in Kalisz   (Poland)

Author keywords

Endothelium; Inflammation; Peripheral vascular disease; Sulodexide

Indexed keywords

INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; SCATTER FACTOR; SULODEXIDE; TISSUE PLASMINOGEN ACTIVATOR; VASCULOTROPIN;

ADSORPTION; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CELL PROLIFERATION; CLINICAL ARTICLE; ENDOTHELIUM; ENDOTHELIUM CELL; FIBRINOLYSIS; HOMEOSTASIS; HUMAN; IN VITRO STUDY; MALE; OXIDATIVE STRESS; PERIPHERAL VASCULAR DISEASE;

ANTICOAGULANTS; BIOLOGICAL MARKERS; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; GLYCOSAMINOGLYCANS; HEPATOCYTE GROWTH FACTOR; HOMEOSTASIS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INJECTIONS, INTRAVENOUS; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULITIS;

EID: 84896822941     PISSN: 18961126     EISSN: 18984002     Source Type: Journal    
DOI: 10.2478/ams-2013-0016     Document Type: Article

References (25)

1. Ofosu F. Pharmacological actions of sulodexide. Semin Thromb Hemost. 1998;24(2):127-38.
2. Karoń J, Polubinska A, Antoniewicz AA, Sumińska- Jasińska K, Breborowicz A. Anti-inflammatory effect of sulodexide during acute peritonitis in rats. Blood Purif. 2007;25(5-6):510-4.
3. Ciszewicz M, Polubinska A, Antoniewicz A, Suminska-Jasinska K, Breborowicz A. Sulodexide suppresses inflammation in human endothelial cells and prevents glucose cytotoxicity. Transl Res. 2009;153(3):118-23.
4. Suminska-Jasinska K, Polubinska A, Ciszewicz M, Mikstacki A, Antoniewicz A, Breborowicz A. Sulodexide reduces senescence-related changes in human endothelial cells. Med Sci Monit. 2011;17(4):CR222-6.
5. Borawski J, Dubowski M, Pawlak K, Mysliwiec M. Sulodexide induces hepatocyte growth factor release in humans. Eur J Pharmacol. 2007;558(1-3):167-71.
6. Nakamura T, Sakai K, Nakamura T, Matsumoto K. Hepatocyte growth factor twenty years on: Much more than a growth factor. J Gastroenterol Hepatol. 2011;26 Suppl 1: 188-202.
7. Borawski J, Dubowski M, Pawlak K, Mysliwiec M. Effect of sulodexide on plasma transforming growth factorbeta1 in healthy volunteers. Clin Appl Thromb Hemost. 2010;16(1):60-5.
8. Lauver DA, Booth EA, White AJ, Poradosu E, Lucchesi BR. Sulodexide attenuates myocardial ischemia/ reperfusion injury and the deposition of C-reactive protein in areas of infarction without affecting hemostasis. J Pharmacol Exp Ther. 2005;312(2):794-800.
9. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193(1):265-75.
10. Fracasso A, Baggio B, Masiero M, Bonfante L, Bazzato G, Feriani M, et al. Effect of oral treatment with the glycosaminoglycan sulodexide on peritoneal transport in CAPD patients. Perit Dial Int. 2003;23(6):595-9.
11. Seidel C, Hjorth-Hansen H, Bendz B, Borset M, Sandset PM, Hansen JB, et al. Hepatocyte growth factor in serum after injection of unfractionated and low molecular weight heparin in healthy individuals. Br J Haematol. 1999;105(3):641-7.
12. Salbach PB, Brückmann M, Turovets O, Kreuzer J, Kübler W, Walter-Sack I. Heparin-mediated selective release of hepatocyte growth factor in humans. Br J Clin Pharmacol. 2000;50(3):221-6.
13. Detmar M, Brown LF, Schön MP, Elicker BM, Velasco P, Richard L, et al. Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol. 1998;111(1):1-6.
14. Celletti FL, Waugh JM, Amabile PG, Brendolan A, Hilfiker PR, Dake MD. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med. 2001;7(4):425-9.
15. Okada M, Matsumori A, Ono K, Miyamoto T, Takahashi M, Sasayama S. Hepatocyte growth factor is a major mediator in heparin-induced angiogenesis. Biochem Biophys Res Commun. 1999;255(1):80-7.
16. Sengupta S, Gherardi E, Sellers LA, Wood JM, Sasisekharan R, Fan TP. Hepatocyte growth factor/scatter factor can induce angiogenesis independently of vascular endothelial growth factor. Arterioscler Thromb Vasc Biol. 2003;23(1):69-75.
17. Barbanti M, Guizzardi S, Calanni F, Marchi E, Babbini M. Antithrombotic and thrombolytic activity of sulodexide in rats. Int J Clin Lab Res. 1992;22(3):179-84.
18. Mauro M, Palmieri GC, Palazzini E, Barbanti M, Calanni Rindina F, Milani MR. Pharmacodynamic effects of single and repeated doses of oral sulodexide in healthy volunteers. A placebo-controlled study with an entericcoated formulation. Curr Med Res Opin. 1993;13(2):87-95.
19. Kim SB, Kim SH, Lee MS, Chang JW, Lee SK, Park JS. Effects of sulodexide on hemostatic factors, lipid profile and inflammation in chronic peritoneal dialysis patients. Perit Dial Int. 2007;27(4):456-60.
20. Bilinska M, Wolszakiewicz J, Duda M, Janas J, Beresewicz A, Piotrowicz R. Antioxidative activity of sulodexide, a glycosaminoglycan, in patients with stable coronary artery disease: a pilot study. Med Sci Monit. 2009;15(12):CR618-23.
21. Skrha J, Perusicová J, Kvasnicka J, Hilgertová J. The effect of glycosaminoglycan sulodexide on oxidative stress and fibrinolysis in diabetes mellitus. Sb Lek. 1998;99(2): 103-9.
22. Shu J, Zeng LY, Lin KY, Mu PW, Zhang GC, Chen YM, Wang MM. [Renal protective effects of sulodexide in diabetic rats and its anti-oxidative mechanism]. Nan Fang Yi Ke Da Xue Xue Bao. 2009;29(4):778-80. Chinese.
23. Colantoni A, Duffner LA, De Maria N, Fontanilla CV, Messingham KA, Van Thiel DH, et al. Dose-dependent effect of ethanol on hepatic oxidative stress and interleukin-6 production after burn injury in the mouse. Alcohol Clin Exp Res. 2000;24(9):1443-8.
24. Elmarakby AA, Sullivan JC. Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy. Cardiovasc Ther. 2012;30(1):49-59.
25. Lasierra-Cirujeda J, Coronel P, Aza M, Gimeno M. Use of sulodexide in patients with peripheral vascular disease. J Blood Med. 2010;1:105-15.